Biomarkers /
AXL
Overview
AXL receptor tyrosine kinase (AXL) is a gene that encodes a protein that belongs to the Tyro3-Axl-Mer (TAM) receptor tyrosine kinase family. The protein functions in cell signal transduction by binding to vitamin K-dependent protein growth arrest specific 6 (Gas6). Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, skin cancer, and stomach cancer.
AXL is altered in 2.00% of all cancers with colon adenocarcinoma, lung adenocarcinoma, cutaneous melanoma, endometrial endometrioid adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in AXL are AXL Mutation (1.69%), AXL Amplification (0.21%), AXL H292fs (0.09%), AXL Loss (0.09%), and AXL Fusion (0.04%) [3].
Clinical Trials
Significance of AXL in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.